ICCM
Icecure Medical Ltd
$
1.040
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.050
Open
1.050
VWAP
1.03
Vol
168.11K
Mkt Cap
58.83M
Low
1.010
Amount
173.93K
EV/EBITDA(TTM)
--
Total Shares
47.94M
EV
50.70M
EV/OCF(TTM)
--
P/S(TTM)
15.92
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
914.00K
+38.07%
-0.070
-12.5%
975.50K
-3.51%
-0.065
+8.33%
750.00K
+0.94%
-0.080
-0%
Estimates Revision
The market is revising Downward the revenue expectations for IceCure Medical Ltd (ICCM) for FY2025, with the revenue forecasts being adjusted by -14.82% over the past three months. During the same period, the stock price has changed by -32.03%.
Revenue Estimates for FY2025
Revise Downward
-14.82%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+6.67%
In Past 3 Month
Stock Price
Go Down
-32.03%
In Past 3 Month
2 Analyst Rating
164.42% Upside
Wall Street analysts forecast ICCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCM is 2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
164.42% Upside
Current: 1.040
Low
2.50
Averages
2.75
High
3.00
164.42% Upside
Current: 1.040
Low
2.50
Averages
2.75
High
3.00
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$2.5
2025-03-28
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$2.5
2024-11-27
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2024-11-27
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$2.5
2024-11-08
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2024-11-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$2.5
2024-09-12
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2024-09-12
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$3 → $2.5
2024-08-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3 → $2.5
2024-08-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2024-07-02
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2024-07-02
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Icecure Medical Ltd (ICCM.O) is -4.29, compared to its 5-year average forward P/E of -5.27. For a more detailed relative valuation and DCF analysis to assess Icecure Medical Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.27
Current PE
-4.29
Overvalued PE
2.20
Undervalued PE
-12.75
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
14.82
Current PS
9.44
Overvalued PS
30.86
Undervalued PS
-1.21
Financials
Annual
Quarterly
FY2024Q4
YoY :
-30.28%
875.00K
Total Revenue
FY2024Q4
YoY :
+32.50%
-4.53M
Operating Profit
FY2024Q4
YoY :
+49.55%
-4.48M
Net Income after Tax
FY2024Q4
YoY :
+14.29%
-0.08
EPS - Diluted
FY2024Q4
YoY :
+76.10%
-4.20M
Free Cash Flow
FY2024Q4
YoY :
+5.12%
47.66
Gross Profit Margin - %
FY2024Q4
YoY :
-4.86%
-383.90
FCF Margin - %
FY2024Q4
YoY :
+114.49%
-511.89
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ICCM News & Events
Events Timeline
2025-04-30 (ET)
2025-04-30
08:39:05
IceCure Medical reports on FDA meeting for ProSense Cryoablation
2025-03-24 (ET)
2025-03-24
08:34:37
IceCure Medical announces interim results from ICESECRET study
2025-03-20 (ET)
2025-03-20
08:34:12
IceCure Medical in discussions with FDA on marketing request for ProSense
Sign Up For More Events
Sign Up For More Events
News
9.0
05-06PRnewswireIceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
1.0
04-28PRnewswireIceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
9.0
04-22PRnewswireIceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
Sign Up For More News
People Also Watch
AMZN
Amazon.com Inc
205.590
USD
+0.20%
WMT
Walmart Inc
98.240
USD
+1.96%
AAPL
Apple Inc
211.260
USD
-0.09%
NVDA
NVIDIA Corp
135.400
USD
+0.42%
AVGO
Broadcom Inc
228.610
USD
-1.73%
XOM
Exxon Mobil Corp
108.190
USD
-0.36%
TSLA
Tesla Inc
349.980
USD
+2.09%
ORCL
Oracle Corp
160.490
USD
+0.68%
MSFT
Microsoft Corp
454.270
USD
+0.25%
META
Meta Platforms Inc
640.340
USD
-0.55%
FAQ
What is Icecure Medical Ltd (ICCM) stock price today?
The current price of ICCM is 1.04 USD — it has increased 0.97 % in the last trading day.
What is Icecure Medical Ltd (ICCM)'s business?
What is the price predicton of ICCM Stock?
What is Icecure Medical Ltd (ICCM)'s revenue for the last quarter?
What is Icecure Medical Ltd (ICCM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Icecure Medical Ltd (ICCM)'s fundamentals?
How many employees does Icecure Medical Ltd (ICCM). have?